EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 329 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma MOST POPULAR Fewer Women with Ovarian, Breast Cancer Undergo Genetic Testing than Expected April 9, 2019 EMA Recommends Extension of Indications for Trastuzumab Deruxtecan July 21, 2022 FDA Approves Crizotinib for ALK-positive Inflammatory Myofibroblastic Tumour July 25, 2022 2025 ESMO Society Award recipients announced August 5, 2025 Load more HOT NEWS Making Important Decisions During Cancer: A Survivor’s Story Researchers Discover Potential Way to Hit Elusive Target in Pancreatic Cancer Regular Exercise May Boost Immune Response and Improve Immunotherapy in Breast... Breast Cancer Survivor Earned Yoga Instructor Certification During Chemo. Now She...
